In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 10, 2000, Pages 2883-2886

  Yamazumi, T ^a   Pfaller, M A ^a   Messer, S A ^a   Houston, A ^a   Hollis, R J ^a   Jones, R N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (4 CYANOPHENYL) 2 THIAZOLYL] 2 (2,4 DIFLUOROPHENYL) 1 (1H 1,2,4 TRIAZOL 1 YL) 2 BUTANOL; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CRYPTOCOCCUS NEOFORMANS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SENSITIVITY; FUNGUS IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; COMPARATIVE STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; HUMAN; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; SUPPORT, NON-U.S. GOV'T; THIAZOLES; TRIAZOLES;

EID: 0033798008     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.10.2883-2886.2000     Document Type: Article

References (18)

1. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones
2. The hidden danger of primary fluconazole prophylaxis for patients with AIDS
3. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus associated cryptococcosis
4. In vitro activities of BMS-207147 against over 600 contemporary clinical blood stream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America
5. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
6. Emergence of cryptococcal disease: Epidemiologic perspectives 100 years after its discovery
7. In vitro and in vivo activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
8. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis and cryptococcosis
9. Cryptococcosis in the era of AIDS - 100 Years after the discovery of Cryptococcus neoformans
10. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates
11. In vitro activities of voriconazole, fluconazole and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
12. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
13. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
14. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole
15. Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives